Cell News and Research

RSS

Signaling pathway reveals mechanism for B cell differentiation in immune response

An article in Science Signaling by researchers at the RIKEN Research Center for Allergy and Immunology (RCAI) has clarified for the first time the mechanism governing differentiation of B cells into antibody-producing plasma cells. The finding establishes a role for the extracellular signal-regulated kinase (ERK) signaling pathway in B cell differentiation, a key step toward the development of B cell-targeted drugs for treatment of autoimmune diseases and allergies.

25 Apr 2011

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

25 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Simple, obvious and obscure ways to keep minds sharp and brains healthy

From a glance at the magazine stands, Americans appear obsessed with losing weight, cutting their cardiac risks and seeking to improve their odds against cancer. But where's the focus on brain health?

25 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

New research provides insight into mechanism behind cardiac development

During embryonic development, cells migrate to their eventual location in the adult body plan and begin to differentiate into specific cell types. Thanks to new research at the University of Pennsylvania, there is new insight into how these processes regulate tissues formation in the heart.

25 Apr 2011

New findings can lead to better understanding of neurological development, cancer metastasis

By shedding new light on how cells migrate in the developing brain, researchers at Fred Hutchinson Cancer Research Center also may have found a new mechanism by which other types of cells, including cancer cells, travel within the body.

25 Apr 2011

U-M receives Taubman Institute's $100 million gift for innovative medical science

A. Alfred Taubman has become U-M's largest individual donor, with total giving of more than $142 million. His latest gift of $56 million to the A. Alfred Taubman Medical Research Institute, announced today before the University's Board of Regents, will bring his support of innovative medical science at the University of Michigan to a total of $100 million.

25 Apr 2011

Research sheds light on molecular movements of neural transporters

A team of scientists from Columbia University College of Physicians and Surgeons and Weill Cornell Medical College has shed light on the molecular workings of transporter proteins, molecular machines embedded in the cell membranes of neurons that modulate the transfer of signals between cells and recycle neurotransmitters.

25 Apr 2011

GM-CSF appears to be key culprit in multiple sclerosis onset

Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis, and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.

25 Apr 2011

Nano Terra, Kadmon sign deal to license novel product candidates

25 Apr 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

Molecular Templates to present preclinical data of ETB platform technology at 5th RNAi and miRNA World Congress

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of small biologic therapies called Engineered Toxin Bodies (ETB), announced today that it will present preclinical data in a poster presentation at the 5th Annual RNAi and miRNA World Congress in Boston, MA during April 26-27, 2011.

22 Apr 2011

Avita's ReCell Spray-On Skin exhibits potential for applications relating to healing of acute wounds

Avita Medical Ltd., the regenerative medicine company, announced today that a clinical study of 18 patients suffering from partial-thickness burns, some of which had failed to heal after treatment with other wound-healing methods ('chronic wounds'), demonstrated successful wound-healing after being treated with ReCell® Spray-On Skin™ from Avita Medical.

22 Apr 2011

Roswell Park Cancer Institute named Blue Distinction Center for Transplants

Roswell Park Cancer Institute (RPCI) has been named a Blue Distinction Center for Transplants® by BlueCross BlueShield of Western New York for demonstrating better overall quality of care and patient results in bone marrow/stem cell (autologous and allogeneic) procedures.

22 Apr 2011

Transplanting cells from healthy adult livers may help treat genetic liver-lung disorder

Transplanting cells from healthy adult livers may work in treating a genetic liver-lung disorder that affects millions of people worldwide, according to an animal study in the April 18 online edition of the Journal of Clinical Investigation.

22 Apr 2011

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

U.S. Congressman Rush Holt (R-12th) visited the headquarters of VaxInnate Corporation today, where he congratulated the biotechnology company on having received a U.S. government contract to fund development of the next generation of flu vaccines and called for more technology investments to improve the health of all Americans.

22 Apr 2011

Cell News and Research

Signaling pathway reveals mechanism for B cell differentiation in immune response

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Nausea and vomiting are most feared of all chemotherapy-related side effects

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Simple, obvious and obscure ways to keep minds sharp and brains healthy

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

New research provides insight into mechanism behind cardiac development

New findings can lead to better understanding of neurological development, cancer metastasis

U-M receives Taubman Institute's $100 million gift for innovative medical science

Research sheds light on molecular movements of neural transporters

GM-CSF appears to be key culprit in multiple sclerosis onset

Nano Terra, Kadmon sign deal to license novel product candidates

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

Study shows neutralizing antibodies against GM-CSF can halt MS development

Molecular Templates to present preclinical data of ETB platform technology at 5th RNAi and miRNA World Congress

Avita's ReCell Spray-On Skin exhibits potential for applications relating to healing of acute wounds

Roswell Park Cancer Institute named Blue Distinction Center for Transplants

Transplanting cells from healthy adult livers may help treat genetic liver-lung disorder

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News